 Recruitment of Patients: Subjects will be recruited from the psychiatry clinics of Alegent-Creighton Clinics where the PI is working on a full-time basis. Dr. Selvaraj, the PI of this project, provides psychiatric care annually to an average of 300 patients with schizophrenia and bipolar disorder. In addition, other psychiatrists in the same clinic also see patients with schizophrenia. Thus, there is an ample population available for this study. The patients will be recruited based on the inclusion and exclusion criteria, as shown in Figure 1. Patients with schizophrenia who are on the atypical antipsychotic, quetiapine, will be recruited. The underlying major mechanism of action of this anti-psychotic medication is to block both dopamine D2 and D4 and serotonin 5-HT2A and 5-HT2c receptors 24. Also, this antipsychotic medication has been shown to increase weight in the patients. According to the data, mean increase in weight after 8-10 weeks on anti-psychotics is about 12.2 lbs with quetiapine 24. In most cases, increase in weight reaches to a plateau within 8-10 weeks 24. Therefore, we will recruit age-matched patients who have been taking quetiapine 100mg or more for at least 12 weeks. There is no relationship in weight gain and the severity of psychosis or the dose of the anti-psychotic drug. During the first episode, most of these patients are in their 20s and 30s. The patients will be divided into two experimental groups: i Weight gain and ii No weight gain. In the weight gain group, we will recruit those patients who have gained 10 increase from the baseline weight. In the no weight group, we will recruit patients who have lost weight, did not gain weight or have gained weight 5 over the baseline weight. The baseline weight data and other information will be obtained from the electronic health record through the EPICS system, upon recruitment in the study. 